شبكة المعلومات الجامعية

التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم

HANAA ALY

شبكة المعلومات الجامعية

التوثيق الالكتروني والميكروفيلم

HANAA ALY

شبكة المعلومات الجامعية

التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات

يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار

HANAA ALY

Estimation of Progression Free Survival (PFS) in patients with hormone positive metastatic breast cancer in cohort of Egyptian patients (Retrospective Cohort Study)

A Thesis

Submitted for Partial Fulfillment of Master Degree In
Clinical Oncology & Nuclear Medicine

By

Ahmed Mohammed El-Saeed Abd El-Fattah
M.B, B.Ch,

Under Supervision of

Prof. Ali Mohammed Azmy
Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

Prof. Mohammed Sabry EL-Qady
Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

Assist. Prof. Amr Shafik
Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine – Ain Shams University

Faculty of Medicine
Ain Shams University
2021

سورة البقرة الآية: ٣٢

Acknowledgments

*First of all, thanks to **Allah**, Most Merciful and compassionate. Without the help of **Allah**, nothing could be done.*

*I would like to express my sincere gratitude and deep appreciation to **Prof. Ali Mohammed Azmy**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine Ain Shams University, for his continuous scientific guidance. Words cannot adequately express my great thanks and gratitude to him. I really have the honor to complete this work under his supervision.*

*I would like to express my sincere gratitude to **Dr. Mohammed Sabry El-Qady**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine Ain Shams, for his valuable help, cooperation, and encouragement without which this work wouldn't be completed.*

*I would like to express my great thanks to **Assist. Prof. Dr. Amr Shafik**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine Ain Shams, for his valuable help, cooperation, and encouragement without which this work wouldn't be completed.*

*I can't forget to thank with all appreciation all members of my **Family**, specially my dear **Mother** and commemorating the death of my **dear Father**, who his memory will be with me always, I will be grateful for their support and their great role in my life and numerous sacrifices for me and for my sisters; may Allah bless his soul.*

Last but not least, many thanks for my Sisters and my Wife for their support.

Ahmed Mohamed El-Saeed

List of Contents

List of Abbreviations

Abbr.		Full-term
AI	**:**	Aromatasei inhibitor
AR	**:**	Androgen receptor
ASCO	**:**	American Society of Clinical Oncology
BCI	**:**	Breast cancer index
BL1	**:**	Basal-like 1
BL2	**:**	Basal-like 2
BLIA	**:**	Basal like immune activated
BLIS	**:**	Basal-like immunosuppressed
CDC	**:**	Centers for Disease Control and Prevention
DCIS	**:**	Ductal carcinoma in situ
DFS	**:**	Disease-free survival
dMFS	**:**	Distant metastasis-free survival
ER	**:**	Estrogen Receptor
GEP	**:**	Gene expression profiling
GGI	**:**	Genomic Grade Index
GR	**:**	Glucocorticoid receptor
HER2	**:**	Human epidermal growth factor receptor 2
HR	**:**	Hormone receptor
IBC	**:**	Invasive breast cancer
IM	**:**	Immunomodulatory
LAR	**:**	Luminal androgen receptor
LCIS	**:**	Lobular carcinoma in situ
MAPK	**:**	Mitogen activated protein kinase

MBC	**:**	Metastatic breast cancer
MC	**:**	Molecular classification
MES	**:**	Mesenchymal
MSL	**:**	Mesenchymal stem-like
OS	**:**	Overall survival
PAM50	**:**	Prediction Analysis of Microarrays 50
pCR	**:**	Pathological complete response
PFS	**:**	Progression free survival
PgR	**:**	Progesterone receptor
QNBC	**:**	Quadruple negative breast cancer
ROR	**:**	Risk-of-recurrence
RS	**:**	Recurrence score
RTK	**:**	Receptor tyrosine kinase
SPSS	**:**	Statistical Package for Social Science
SEER	**:**	Surveillance, Epidemiology, and End Results
SREs	**:**	Skeletal-related events
TNBC	**:**	Triple negative breast cancer
TNF	**:**	Tumor necrotic factor

List of Tables

List of Figures

Introduction

Breast cancer is the most common type of cancer diagnosed in women, comprising 30% of all women's cancer diagnoses in the United States. The American Cancer Society estimated that 252, 710 new cases of breast cancer were diagnosed in women in 2017 (along with about 2470 cases in men). Breast cancer is the second leading cause of cancer-related death in women after lung cancer, accounting for 12% of cancer-related deaths **(Siegel et al., 2017)**.

The use of systemic therapies such as hormonal therapy, chemotherapy or new biological treatment is to reduce tumour masses, improve survival and preserve quality of life. Whatever the initial efficacy of the treatment undertaken in metastatic setting, almost every patient will relapse. The main goal is to improve progression free survival (PFS) **(Dickson et al., 2005)**.

Michiels et al. (2016) assessed to what extent PFS may be used as a surrogate for OS in randomized trials of anti-HER2 agents in HER2+ MBC. PFS moderately correlates with OS at the individual level and treatment effects on PFS correlate moderately with those on overall mortality, providing only modest support for considering PFS as a surrogate. PFS does not completely substitute for OS in this setting.